<DOC>
	<DOCNO>NCT00434434</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel-group , three-arm , placebo-controlled study design demonstrate efficacy two different formulation omalizumab compare placebo reduce airway reaction inhale aeroallergen solution adult subject mild allergic asthma .</brief_summary>
	<brief_title>A Study Omalizumab Prevention Allergen Induced Airway Obstruction Adults With Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Informed Consent Form Meet criterion diagnosis allergic asthma Be age 18 65 year Have normal chest Xray within 2 year screen Need daily controller medication asthma History hypersensitivity study drug drug similar chemical structure ingredient , include excipients study medication drug relate omalizumab ( e.g. , monoclonal antibody , polyclonal gamma globulin ) Have document medical history anaphylaxis Have lung disease mild allergic asthma Have take investigational drug within 30 day 5 halflives prior screen visit , whichever long Are unable unwilling comply study procedure visit Are pregnant lactate Have significant medical illness asthma , include malignancy , parasitic infection , immune system disorder , thrombocytopenia Have treat omalizumab within 12 month prior screen Currently smoke history smoking 10 packyears Have history drug alcohol abuse , , judgment investigator , may put subject risk unable participate fully study duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>AQUA</keyword>
	<keyword>anti-CD11</keyword>
	<keyword>CD11a</keyword>
	<keyword>Asthma</keyword>
	<keyword>Allergy</keyword>
</DOC>